Drugs that contain Metformin Hydrochloride; Saxagliptin Hydrochloride
1. Drug name - KOMBIGLYZE XR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(10 months from now) | |
| CN1698601A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2010
(12 years ago) | |
| CN1427826A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| CN1213028C | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| IN206543B | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| IN200201154P3 | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| EP2272825A3 | ASTRAZENECA AB | N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 6 months ago) | |
| EP2272825A2 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 6 months ago) | |
| EP2995615A1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 6 months ago) | |
| EP2272825B1 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 6 months ago) | |
| EP2995615B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 6 months ago) | |
| EP1559710B1 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 6 months ago) | |
| EP1559710A3 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 6 months ago) | |
| EP1559710A2 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 6 months ago) | |
| EP1261586B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| EP1261586A2 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) | |
| US9339472 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) | |
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 1GM;EQ 2.5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 1GM;EQ 5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 500MG;EQ 5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.